|Mr. Cathal Martin Friel||Exec. Chairman||N/A||N/A||1965|
|Dr. Yamin Mohammed Khan Ph.D.||CEO & Director||N/A||N/A||1970|
|Mr. Leo Toole||Group CFO & Director||N/A||N/A||1973|
|John Sheridan||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Andrew Catchpole||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Maurice N. Treacy Ph.D.||Chief Commercial Officer||N/A||N/A||N/A|
Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.
Open Orphan Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.